Ποια είναι η τιμή για Viking Therapeutics, Inc. (VKTX)

Η τιμή για Viking Therapeutics, Inc. (VKTX) είναι $34.49

Ποια είναι η κεφαλαιοποίηση αγοράς για Viking Therapeutics, Inc. (VKTX)

Η κεφαλαιοποίηση αγοράς για Viking Therapeutics, Inc. (VKTX) είναι $4.02B

Viking Therapeutics, Inc. (VKTX) Δείκτης P/S

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Έτος	P/S Ratio	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

P/S Ratio

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	P/S Ratio	Διαφορά P/S Ratio	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

Εταιρεία

P/S Ratio

Διαφορά P/S Ratio

Χώρα